Companies Sanofi and NANOLEK announced a new stage in the development of a long-term partnership to localize the full-cycle production in Russia of a five-component combined pediatric vaccine developed by Sanofi, in particular, successful bottling of validation series.
At the biomedical production complex of NANOLEK in Kirov, the stability of three validation series of a five-component combined pediatric vaccine is being studied with the participation of representatives of Sanofi. Under the Technology Transfer Agreement, during the established period, quality control will be carried out.
Vladimir Khristenko, President of NANOLEK:
"We are happy that our partnership with Sanofi Pasteur has entered a new era. Multi-component vaccines are a modern and important instrument to combat vaccine-controlled infections. We hope that the new stage of localization - the full-cycle production of the finished dosage form will remove all barriers to the inclusion of the five-component combined pediatric vaccine in the National Calendar of Preventive Vaccinations for all children, and not just for risk groups. The pandemic has shown how acute the vaccination issue may be, and that we can all be at risk at any time."
Frederick Jumel, General Manager of Sanofi Pasteur Eurasia:
"Over the last years, Sanofi Pasteur and Nanolek have contributed significantly to the fight against vaccine-controlled infections. Thanks to the mutual efforts, we have passed another essential step in the project to localize our five-component pediatric vaccine production, which means we are one step closer to our common goal: to protect all Russian children against dangerous infections. In the context of the challenges the world is facing today, issues of increasing vaccination coverage and effective disease control are stepping forward. Thanks to the implementation of our project, we can make a significant contribution to solving these problems".
Nikolay Briko, Head of the Department of Epidemiology and Evidence-Based Medicine, First Moscow State Medical University named after I.M. Sechenov, M.D., an academician of the Russian Academy of Sciences, Professor, Honored Worker of Russian Science, chief freelance epidemiologist of the Ministry of Health of the Russian Federation:
"I see great potential in collaboration between Sanofi and NANOLEK; it helps us to introduce advanced technologies for the production of vaccines in the Russian Federation. The product quality meets high international standards. And most importantly, in this case, we are talking about a combined vaccine. Combined vaccines can reduce the number of injections, especially for children in their first two years of life, as well as the costs of administering, storing, and trafficking medications throughout the multi-faceted supply chain."
About the Partnership Project of Sanofi and NANOLEK
NANOLEK and Sanofi are united by a common goal - the protection of Russian children against vaccine-controlled infections. In achieving this goal, Sanofi Pasteur and NANOLEK have already made a notable success.
The cooperation agreement was signed in 2016. Since 2017, the vaccine has been successfully supplied as part of the National Calendar of Preventive Vaccinations. In 2019, a 2-year state contract was concluded for the first time (for 2019-2020) for the supply of vaccines to the NKPP. Under the agreement, NANOLEK entirely performed the obligations of the first year: the first phase of the delivery of a pediatric five-component combined vaccine was completed. In total, 3.5 million doses of the vaccine were produced and delivered in 2019 - this helped protect about 1 million children against five dangerous infections: tetanus, pertussis, diphtheria, poliomyelitis, and Haemophilus influenza type b.
